(Q45441520)

14 December 2017

Viral dynamics during tenofovir therapy in patients infected with lamivudine-resistant hepatitis B virus mutants (English)

1 reference

14 December 2017

1 reference

1 reference

2

1 reference

14 December 2017

3

1 reference

14 December 2017

van der Eijk AA

1

1 reference

14 December 2017

Janssen HL

4

1 reference

14 December 2017

van de Ende M

5

1 reference

14 December 2017

Schalm SW

6

1 reference

14 December 2017

de Man RA

7

1 reference

14 December 2017

1 July 2005

1 reference

Journal of Viral Hepatitis

14 December 2017

1 reference

14 December 2017

12

1 reference

14 December 2017

4

1 reference

14 December 2017

364-372

1 reference

Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial

14 December 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00620.X

Long-term therapy of chronic hepatitis B with lamivudine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00620.X

Persistence of YMDD variants after withdrawal of Lamivudine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00620.X

Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00620.X

Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00620.X

Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00620.X

Rapid hepatitis B virus-DNA decay in co-infected HIV-hepatitis B virus 'e-minus' patients with YMDD mutations after 4 weeks of tenofovir therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00620.X

An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00620.X

Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00620.X

Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00620.X

Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00620.X

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00620.X

Viral dynamics in chronic hepatitis B patients during lamivudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00620.X

Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00620.X

Viral dynamics in hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00620.X

Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00620.X

Analysis of hepatitis B viral load decline under potent therapy: complex decay profiles observed.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00620.X

Identification of a new variant in the YMDD motif of the hepatitis B virus polymerase gene selected during lamivudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00620.X

The influence of baseline characteristics on viral dynamic parameters in chronic hepatitis B patients treated with lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00620.X

10.1111/J.1365-2893.2005.00620.X

21 January 2018

Identifiers

DOI

1 reference

14 December 2017

1 reference